estim top bottom line albeit hand newer product miss
quarterli expect ep guidanc rais revenu guidanc narrow upper
end rang
ep estim consensu
ep guidanc increas vs prior rais ep
estim beyond estim review
sale estim
consensu drug beat estim includ ciali gener launch
late septemb cymbalta strattera effient taltz verzenio
olumi combin forecast product
forecast includ trulic basaglar tradjenta zyprexa jardianc cyramza
alimta combin light humalog sale line
gpm higher estim flat
estim sg higher forecast
net non-oper expens higher estim pre-tax margin
estim tax rate estim
ad ep share count higher forecast
sale guidanc narrow vs prior last publish
estim gpm guidanc unchang sg guidanc rang
narrow vs prior rang incom guidanc
unchang tax rate guidanc lower approxim vs prior approxim
verzenio ph ii data monarch w/herceptin bc late taltz file
axspa emgal cgrp eu approv migrain prevent posit chmp sept file
cluster headach olumi initi ph jardianc initi ph ckd tirzepatid
initi ph late
pleas see page report import disclosur
number promis new drug rollout late-stag agent pois launch
next year give us confid top-tier sale ep growth prospect pipelin
visibl improv overal margin target appear achiev estim
ep compound-annual-growth-rate among best pharma dividend yield attract
taltz psoriasi psoriat arthriti
perform diabet busi
full trulic rewind data ada
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
margin expans sooner greater
alimta declin rapidli
margin expans plan delay
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas
oncolog among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
